Skip to main content

Colorectal Cancer Clinical Trials

Review the colorectal cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 441

Ciprofloxacin, Metronidazole, and Aspirin with Standard of Care Chemotherapy in Patients with Stage IV Colorectal Cancer Undergoing First-Line Therapy
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
TAS-102 With or Without Celecoxib for the Treatment of ctDNA-Defined Minimal Residual Disease Stage II-IV Colorectal Cancer after Completion of Chemotherapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fruquintinib and Tislelizumab for the Treatment of Colorectal Cancer in Patients with Minimal Residual Disease after Chemotherapy Treatment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immunotherapy (Dostarlimab) for the Treatment of Stage II and III Deficient Mismatch Repair Colon Cancer
Status: Active
Location: 2 locations
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Hydroxychloroquine in Combination with Encorafenib and Cetuximab or Panitumumab in Treating Patients with Stage IV BRAF-Mutated Colorectal Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
AMB-05X for Treating Patients with ctDNA(+) Stage I-IV Colorectal Cancer after Curative-Intent Treatment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Botensilimab and Balstilimab with Combination Chemotherapy for the Treatment of Patients with Metastatic Microsatellite Stable Colorectal Cancer
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Cemiplimab with or without Fianlimab for the Treatment of Older Patients with Localized or Locally Advanced MSI-H Colorectal Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Regorafenib in Combination with Pembrolizumab or Pembrolizumab Alone for the Treatment of Metastatic or Unresectable MSI-H Colorectal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Flat Dose or Weight-Based Dose of Mitomycin during Cytoreductive Surgery for the Treatment of Advanced Gastrointestinal Malignancy
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Pembrolizumab in Combination with Odetiglucan for the Treatment of Patients with Metastatic Colorectal Cancer with Liver Metastases
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Microsatellite Stable Localized Rectal Cancer before Surgery
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Ivonescimab for the Treatment of Patients with Previously Treated Metastatic Colorectal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Metronidazole to Reduce the Tumor Associated Bacteria of Rectal Adenocarcinoma in Patients Receiving Neoadjuvant Therapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ctDNA-Directed Chemotherapy after Hepatectomy for the Treatment of Colorectal Liver Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Enfortumab Vedotin for the Treatment of Patients with Unresectable or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Avutometinib, Defactinib and Cetuximab for the Treatment of Patients with Unresectable or Metastatic, Refractory Colorectal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tertiary and Community Care Models for the Administration of Hepatic Artery Infusion Chemotherapy in Patients with Unresectable or Resectable Colorectal Liver Metastases and Unresectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Lenvatinib and Pembrolizumab for the Treatment of Unresectable, Locally Advanced, or Metastatic Anorectal Squamous Cell Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Biomarkers for Predicting Response to SAR444881 in Combination with Cemiplimab in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, or Ovarian Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas